Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 9/20 | 0.63 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.63 |
| ▸ | RAF1 | P04049 | 2/20 | 0.63 |
| ▸ | KDR | P35968 | 2/20 | 0.63 |
| ▸ | MAP2K2 | P36507 | 2/20 | 0.63 |
| ▸ | TGFBR2 | P37173 | 2/20 | 0.63 |
| ▸ | NEK2 | P51955 | 2/20 | 0.63 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.63 |
| ▸ | TNK2 | Q07912 | 2/20 | 0.63 |
| ▸ | MAP2K5 | Q13163 | 2/20 | 0.63 |
| ▸ | PTK6 | Q13882 | 2/20 | 0.63 |
| ▸ | NEK11 | Q8NG66 | 2/20 | 0.63 |
| ▸ | MAP3K20 | Q9NYL2 | 2/20 | 0.63 |
| ▸ | MAP4K5 | Q9Y4K4 | 2/20 | 0.63 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.63 |
| ▸ | PLK4 | O00444 | 1/20 | 0.63 |
| ▸ | PIR | O00625 | 1/20 | 0.63 |
| ▸ | AURKA | O14965 | 1/20 | 0.63 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.63 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3507259 | 0.92 | BRAF (0.55) | BRAFRIPK2RAF1KDRMAP2K2 | |
| SCHEMBL3505935 | 0.90 | CYP2C19 (0.52) | BRAFRIPK2RAF1KDRMAP2K2 | |
| SCHEMBL3703307 | 0.89 | BRAF (0.51) | BRAFRIPK2RAF1KDRMAP2K2 | |
| SCHEMBL13505689 | 0.89 | BRAF (0.53) | BRAFRIPK2RAF1KDRMAP2K2 | |
| SCHEMBL432500 | 0.88 | BRAF (0.66) | BRAFRIPK2RAF1KDRMAP2K2 | |
| SCHEMBL2354890 | 0.88 | BRAF (0.64) | BRAFRIPK2RAF1KDRMAP2K2 | |
| SCHEMBL2889134 | 0.88 | BRAF (0.63) | BRAFRIPK2RAF1KDRMAP2K2 | |
| SCHEMBL30078249 | 0.87 | BRAF (0.62) | BRAFRIPK2RAF1KDRMAP2K2 | |
| SCHEMBL298199 | 0.87 | BRAF (0.62) | BRAFRIPK2RAF1KDRMAP2K2 | |
| SCHEMBL2886604 | 0.87 | CYP2C19 (0.67) | BRAFRIPK2RAF1KDRMAP2K2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8470818-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2013-06-25 | — | — | US | claimed |
| US-20120245174-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2012-09-27 | — | — | US | claimed |
| EP-1893612-B1 | PYRROLO [2, 3-B]PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | PLEXXIKON INC (US) | 2011-08-03 | — | — | EP | claimed |
| US-7863289-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON, INC. (US) | 2011-01-04 | — | — | US | claimed |
| US-20100286142-A1 | Compounds and Methods for Kinase Modulation, and Indications Therefor | PLEXXIKON, INC. | 2010-11-11 | — | — | US | claimed |
| US-20100249118-A1 | protein kinase modulators such as Propane-1-sulfonic acid [2,4-difluoro-3-(5-ethoxy-1H-pyrrolo[1,3-b]pyridine-3-carbonyl)-phenyl]-amide, used to regulate signal transduction cascades, involved in the control of physiological functions including cellular growth and proliferation; anticarcinogenic agents | PLEXXIKON INC. | 2010-09-30 | — | — | US | claimed |
| EP-2097414-A1 | PYRROLO [2, 3-B]PYRIDINE DERIVATIVES AS KINASE MODULATORS | PLEXXIKON, INC. (US) | 2009-09-09 | — | — | EP | claimed |
| US-20080167338-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC | 2008-07-10 | — | — | US | claimed |
| WO-2008079903-A1 | PYRROLO [2, 3-B] PYRIDINE DERIVATIVES AS KINASE MODULATORS | PLEXXIKON, INC. (US) | 2008-07-03 | — | — | WO | claimed |
| WO-2008079906-A1 | PYRROLO [2, 3-B] PYRIDINE DERIVATIVES AS KINASE MODULATORS | PLEXXIKON, INC. (US) | 2008-07-03 | — | — | WO | claimed |
| EP-2958571-B1 | DNA HYPOMETHYLATING AGENTS FOR CANCER THERAPY | MAIO MICHELE (IT) | 2024-04-10 | — | — | EP | disclosed |
| US-20230277534-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2023-09-07 | — | — | US | disclosed |
| US-11337976-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2022-05-24 | — | — | US | disclosed |
| US-20210338701-A1 | DNA HYPOMETHYLATING AGENTS FOR CANCER THERAPY | MAIO MICHELE (IT) | 2021-11-04 | — | — | US | disclosed |
| US-11083743-B2 | DNA hypomethylating agents for cancer therapy | MAIO MICHELE (IT) | 2021-08-10 | — | — | US | disclosed |
| WO-2008079903-A1 | PYRROLO [2, 3-B] PYRIDINE DERIVATIVES AS KINASE MODULATORS | PLEXXIKON, INC. (US) | 2008-07-03 | — | — | WO | disclosed |
| WO-2008079906-A1 | PYRROLO [2, 3-B] PYRIDINE DERIVATIVES AS KINASE MODULATORS | PLEXXIKON, INC. (US) | 2008-07-03 | — | — | WO | disclosed |
| EP-1893612-A1 | PYRROLO [2, 3-B]PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | PLEXXIKON, INC. (US) | 2008-03-05 | — | — | EP | disclosed |
| WO-2007002325-A1 | PYRROLO[2,3-B] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | PLEXXIKON, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| WO-2007002433-A1 | PYRROLO [2, 3-B] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | PLEXXIKON, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249118-A1 | protein kinase modulators such as Propane-1-sulfonic acid [2,4-difluoro-3-(5-ethoxy-1H-pyrrolo[1,3-b]pyridine-3-carbonyl)-phenyl]-amide, used to regulate signal transduction cascades, involved in the control of physiological functions including cellular growth and proliferation; anticarcinogenic agents | MAP4K1, MAP4K2, MAP3K1 | BRAF 95/4885RIPK2 477/4885RAF1 36/4885 |
| US-20080167338-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | BRAF 48/4885RIPK2 514/4885RAF1 78/4885 |
| US-11337976-B2 | Compounds and methods for kinase modulation, and indications therefor | MAP3K20, PRKACA, MAP3K13 | BRAF 49/4885RIPK2 504/4885RAF1 74/4885 |
| US-20230277534-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, PRKACA, MAP3K13 | BRAF 49/4885RIPK2 504/4885RAF1 74/4885 |
| US-20100286142-A1 | Compounds and Methods for Kinase Modulation, and Indications Therefor | BRAF, ARAF, RAF1 | BRAF 1/4885RIPK2 1064/4885RAF1 3/4885 |
| US-20120245174-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | BRAF, ARAF, RAF1 | BRAF 1/4885RIPK2 1064/4885RAF1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.